In Brief: CIS bio international
This article was originally published in The Gray Sheet
CIS bio international: French in vitro diagnostics firm expects to launch its Kryptor automated immunoanalyzer with Trace technology in Europe by the end of the calendar year. Trace technology provides "homogeneous immunoanalysis," CIS explains, allowing reactions to be measured directly in solution, thus eliminating the "solid reaction phase or washing" required for standard immunoassays. The 300-well microtiter system initially will be sold with a panel of eight tumor markers, free beta hCG, and AFP. Assays slated to be added in 1997 include: prolactin, LH, FSH, hCG and CYFRA 21-1, estradiol, ferritin, beta-2 microglobulin, testosterone, progesterone, and osteocalin. Cardiac and thyroid tests also are under development...
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.